[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05494398":3,"trial-entities:NCT05494398":84,"trial-summary:NCT05494398":87},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":25,"primary_purpose":26,"phases":27,"enrollment_info":30,"interventions":33,"primary_outcomes":39,"secondary_outcomes":47,"sex":55,"minimum_age":56,"maximum_age":57,"healthy_volunteers":58,"eligibility_criteria":59,"std_ages":65,"locations":67,"central_contacts":77,"overall_officials":78,"references":82,"see_also_links":83},"NCT05494398","IRB-64292","Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label","Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: an Open Label Extension","ENROLLING_BY_INVITATION","2029-01-31","2026-05","2026-05-15","2024-03-12","Stanford University","OTHER",true,"The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder.",null,[19],"Autism Spectrum Disorder",[21,22,23,24],"Magnetic Resonance Imaging","N-acetylcysteine","Restricted and Repetitive Behaviors","Electroencephalography","INTERVENTIONAL","TREATMENT",[28,29],"PHASE2","PHASE3",{"count":31,"type":32},144,"ESTIMATED",[34],{"type":35,"name":22,"description":36,"armGroupLabels":37},"DRUG","12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.",[38],"N-Acetylcysteine",[40,43],{"measure":41,"timeFrame":42},"Change in glutamatergic neurometabolites (Glx) measured by proton spectroscopy Magnetic Resonance Imaging (MRI)","Baseline and Week 12 of treatment",{"measure":44,"description":45,"timeFrame":46},"Change in restricted and repetitive behaviors as measured by Children's Yale Brown Obsessive Compulsive Scale - Autism Spectrum Disorder (CYBOCS-ASD)","Higher scores on the Children's Yale Brown Obsessive Compulsive Scale - Autism Spectrum Disorder mean higher levels of restricted and repetitive behaviors (Raw Score Total Range: 0-20)","Screening, Week 8, week 12",[48,51],{"measure":49,"timeFrame":50},"Change in Gamma band amplitude and synchronization measured by electroencephalography (EEG)","Baseline, Week 12",{"measure":52,"description":53,"timeFrame":54},"Change in restricted repetitive behavior subtypes as measured by the Restricted Behavior Scale - Revised (RBS-R)","Higher scores on the Repetitive Behavior Scale- Revised mean higher levels of repetitive and restricted behaviors. (Raw Score Total Range: 0 - 129)","Baseline, week 8, week 12","ALL","3 Years","13 Years",false,{"inclusion":60,"exclusion":63,"raw_text":64},[61,62],"participation in an associated single-dose (IRB-54931, NCT04278898) or randomized, controlled trial of NAC (IRB- 68353, NCT05664789).","stable medication regimens (≥ 30 days) with no anticipated changes during the trial.",[],"Inclusion Criteria:\n\n* participation in an associated single-dose (IRB-54931, NCT04278898) or randomized, controlled trial of NAC (IRB- 68353, NCT05664789).\n* stable medication regimens (≥ 30 days) with no anticipated changes during the trial.\n\nExclusion criteria:\n\n• the presence of significant medical problems that reduce medical stability.",[66],"CHILD",[68],{"facility":69,"city":70,"state":71,"zip":72,"country":73,"geoPoint":74},"Stanford University School of Medicine","Stanford","California","94305","United States",{"lat":75,"lon":76},37.42411,-122.16608,[],[79],{"name":80,"affiliation":13,"role":81},"John Hegarty, PhD","PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":85,"biomarkers":86},[19],[],{"nct_id":4,"found":58,"summary":17,"prompt_version":17}]